CLINICAL REFERENCE NOTE

Low-Dose Naltrexone (LDN) in Solid Organ Transplant Recipients on Chronic Immunosuppression

Prepared by Yoon Hang Kim, MD, MPH  |  Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician Reviewed: May 2026  |  Internal clinical reference — not patient-facing

1. Clinical question

Can low-dose naltrexone (LDN, typically 1.5–4.5 mg nightly) be used safely in a patient on chronic immunosuppression following solid organ transplantation? The specific worry repeated throughout the LDN literature is that LDN could antagonize the intended immunosuppression and thereby increase the risk of allograft rejection.

2. The standard guidance

Essentially every patient-facing and clinician-facing LDN resource descended from Bernard Bihari’s original work lists organ transplantation on permanent immunosuppression as a caution or relative contraindication. The stated rationale is uniform: transplant recipients are cautioned against LDN because it may act to counter the effect of those medications. Some clinics escalate this to an absolute contraindication, warning that LDN can potentially lead to organ rejection and that it can counter the effect of anti-rejection drugs.

The mechanistic premise behind the warning is that LDN’s transient opioid-receptor blockade upregulates endogenous opioids (endorphins) and “normalizes” immune function — which, in a patient whose immune system is being deliberately suppressed to protect a graft, is presumed to be counterproductive. Importantly, this premise is asserted rather than demonstrated; it is not derived from transplant outcome data.

3. What the evidence actually shows

3a. The warning is theoretical — no human signal

A targeted search of the published literature returns no human case reports, case series, or cohort data documenting LDN-precipitated graft rejection. The contraindication rests on mechanistic reasoning and precaution, not on observed adverse events. There are likewise no clinical trials of LDN in transplant recipients, so there is no direct human safety evidence in either direction.

3b. The transplant-relevant immunology of naltrexone points the other way

When the actual experimental immunology of naltrexone is examined, the net signal is anti-inflammatory and, if anything, mildly immunosuppressive — the opposite of what would be expected to drive rejection:

• Cardiac tissue allograft (murine). Naltrexone significantly prolonged transplanted cardiac tissue survival from 9 to 13 days versus controls; in parallel experiments naltrexone suppressed the mixed-lymphocyte proliferative response (comparable to mitomycin C) and suppressed concanavalin-A–stimulated spleen lymphocyte proliferation, implicating endogenous opioid signaling in immunocyte activation and DNA synthesis (Li et al., 1998).
• TLR4 / innate immunity. Naltrexone antagonizes TLR4/MD-2 signaling. TLR4 is a recognized driver of ischemia/reperfusion injury and allograft rejection, and TLR4 blockade is itself being explored as a strategy to reduce rejection — one bone-allograft group explicitly proposed combining TLR4-pathway inhibition with low-dose immunosuppressants to improve graft outcomes (Liu et al., 2017; Zhao et al., 2024).
• Human immune cells. In human PBMCs, naltrexone inhibited IL-6 and TNFα production by monocytes and plasmacytoid dendritic cells following intracellular TLR (TLR7/8, TLR9) stimulation, without affecting cell viability — a net anti-inflammatory profile (Cant et al., 2017).
• Related opioid antagonists. The delta-opioid antagonist naltrindole has separately been reported to produce immunosuppression in a transplantation context (Arakawa et al., 1993).

Caveat on translation: these are animal and in-vitro studies, several using full pharmacologic naltrexone doses rather than the low, pulsatile exposure achieved with 1.5–4.5 mg LDN. They undercut the simplistic “LDN boosts immunity → rejection” narrative but do not establish that LDN is safe in transplant recipients.

3c. Pharmacokinetic considerations (often overlooked)

Naltrexone is metabolized principally by dihydrodiol dehydrogenase to 6-β-naltrexol and is not heavily CYP-dependent. However, a human liver-microsome study found naltrexone inhibits CYP3A4 (~38% at 1 µM), CYP2C9, and CYP2D6 (AlRabiah et al., 2018). Tacrolimus, cyclosporine, and sirolimus are narrow-therapeutic-index CYP3A4 substrates.

• Direction of effect: CYP3A4 inhibition would tend to raise calcineurin-inhibitor levels (toxicity/over-immunosuppression), not lower them — i.e., it does not support a rejection mechanism.
• Magnitude / clinical relevance: the inhibition was observed at 1 µM in vitro, well above plasma concentrations achieved by a 1.5–4.5 mg LDN dose, so clinically meaningful CYP3A4 inhibition at LDN doses is unlikely. If LDN were ever co-administered, the prudent response is tighter trough monitoring rather than an assumption of no interaction.

4. Synthesis and practical recommendations

The interaction concern is pharmacodynamic and theoretical; there is no human evidence that LDN causes rejection, and the mechanistic data arguably run counter to the lay warning. Nonetheless, because (i) the published cautions are near-universal, (ii) the downside of a rejection event is catastrophic, and (iii) there is zero confirmatory safety data, avoidance remains the defensible default.

• Default position: Do not initiate LDN in solid organ transplant recipients on maintenance immunosuppression outside of a compelling, individualized rationale.
• If genuinely considered (e.g., a stable long-term recipient with a refractory autoimmune or chronic-pain indication for which LDN is otherwise attractive), treat it as off-label use with no safety data and proceed only with: co-management/sign-off from the transplant team; baseline and serial graft-function monitoring; calcineurin-inhibitor (or mTOR-inhibitor) trough monitoring around initiation and dose changes; and explicit, documented informed consent acknowledging the unknowns.
• Patient framing: “We don’t have evidence either way; the precautionary standard says avoid; and the unknowns are not worth gambling a graft over” — unless the indication is compelling and the transplant team concurs.
• Documentation: Record the theoretical (not evidence-based) nature of the rejection concern, the shared decision-making, and the monitoring plan.

5. References

1. Li YF, Wang JX, Shao L, et al. Naltrexone suppresses the rejection of cardiac tissue transplantation. Int J Cardiol. 1998;64 Suppl 1:S23–S27. doi:10.1016/s0167-5273(98)00032-1. PMID 9687089.
2. Cant R, Dalgleish AG, Allen RL. Naltrexone inhibits IL-6 and TNFα production in human immune cell subsets following stimulation with ligands for intracellular Toll-like receptors. Front Immunol. 2017;8:809. PMC5504148.
3. Toljan K, Vrooman B. Low-Dose Naltrexone (LDN) — Review of Therapeutic Utilization. Med Sci (Basel). 2018;6(4):82. doi:10.3390/medsci6040082. PMC6313374.
4. AlRabiah H, Ahad A, Mostafa GAE, Al-Jenoobi FI. Effect of naltrexone hydrochloride on cytochrome P450 1A2, 2C9, 2D6, and 3A4 activity in human liver microsomes. Eur J Drug Metab Pharmacokinet. 2018;43(6):707–713. doi:10.1007/s13318-018-0482-x. PMID 29744741.
5. Knockdown of toll-like receptor 4 signaling pathways ameliorate bone graft rejection in a mouse model of allograft transplantation. Sci Rep. 2017;7:46050. doi:10.1038/srep46050. (nature.com/articles/srep46050)
6. Arakawa K, Akami T, Okamoto M, et al. Immunosuppression by delta-opioid receptor antagonist (naltrindole). Transplant Proc. 1993;25(1 Pt 1):738–740. PMID 8382386.
7. TLR4 signalling in ischemia/reperfusion injury: a target for improving organ transplantation outcomes. PMC11291251 (review). (PMC11291251)
8. LDN Research Trust / Bihari-derived LDN fact sheets and clinic monographs (transplant/immunosuppression caution language). Cited here as the source of the standard contraindication statement, not as primary evidence.

Internal clinical reference prepared for the practice of Yoon Hang Kim, MD, MPH. Off-label and integrative-medicine content; not a substitute for transplant-team judgment. www.directintegrativecare.com